HOME  >   > 
[] 304ȣ (2017.12.12.)
  • ۾
  • ۼ 2017-12-12 18:23:53
  • ȸ 42229
÷ 304.jpg
newsletter

ǰǾǰó ҽ


ǰ ȸ

ľó 4 ô ű Ǿǰ ȯ ȭ ڵ ǰ ݿϿ '18⵵ Ǿǰ 㰡ɻ ̵  ȹ ϰ
  • ǰ: ߰ȼ(1)
  • ǰȸ: ~'17.12.21()
  • ó: ǰ߼ johs8739@kobia.kr ۺ

ο ȳ

Ǿǰ 㰡Ư㿬 (2017-12-12) ߰


̿Ǿǰ ӻ

û
ǰ
p
ѱ ƽƮ
ī
20171211
-PD-1/PD-L1 ġ ߿ Ҽ ȯڸ , , üǥ ߽, ٱ, II, ӻ(HUDSON)
MEDI4736
2

 


ֿ к

̿

, ǥη 4 1899, ѻ 8 9000
۳ ̿ 1 9568 ڡ 13.9%
̿Ǿǰ ǰ 10 6 ϴ 6 ǰ (1 5,429 ) 34.7% ߴ. Ư ̿Ǿǰ Ź․༭ 2,839 311.4% ߴ. 1 4,606 ϸ 3.7% þ. κ ̿Ǿ ǰ 1 2,726 87% ϴ  ġü(21.4%) (31.9%) ݸ, ȣ(39.2%), (7.7%) ߴ. Ҿ 16 ̿ η 41,899 2015 4.0% , ڱԸ 2016 1 9,568 2015 13.9% ߴ.....


̱ 㰡 Ȳ

Drug name Active Ingredients Submission
Classification
Company Approval date
LONHALA MAGNAIR
NDA #208437
GYCOPYRROLATE ſ뷮 SUNOVION 12/05/2017
OZEMPIC
NDA #209637
SEMAGLUTIDE Ź NOVO NORDISK INC 12/05/2017
SINUVA
NDA #209310
MOMETASONE FUROATE ſ뷮 INTERSECT ENT INC 12/08/2017
XEPI
NDA #208945
OZENOXACIN Ź FERRER INTERNACIONAL S.A. 12/11/2017

㰡 Ȳ

Name Active Substance Therapeutic area Date of authorisation/ refusal
Tremfya guselkumab Psoriasis 10/11/2017
Tookad padeliporfin di-potassium Prostatic Neoplasms 10/11/2017
Adlumiz anamorelin hydrochloride Anorexia
Cachexia
Carcinoma,
Non-Small-Cell Lung
16/11/2017

 


̱ ̿Ǿǰ ӻ Ȳ

NCT Number Title Conditions Interventions Sponsor/Collaborators P
NCT03368729

Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer

Metastatic Breast Cancer|HER2 Positive Breast Carcinoma

Drug: Niraparib|Drug: Trastuzumab

University of Alabama at Birmingham|Translational Breast Cancer Research Consortium|Tesaro, Inc.|Susan G. Komen Breast Cancer Foundation|Breast Cancer Research Foundation of Alabama

1
2
NCT03368859

A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine/Oxaliplatin and Bevacizumab

Cancer - Metastatic Colorectal

Drug: ABT-165|Drug: Bevacizumab|Drug: Irinotecan|Drug: Leucovorin|Drug: Fluorouracil - bolus|Drug: Fluorouracil - infusion

AbbVie 2
NCT03367871

Combination Pembrolizumab, Paclitaxel and Cisplatin in Patients With Cervical Cancer

Cervical Cancer

Drug: Pembrolizumab|Drug: Paclitaxel|Drug: Cisplatin

University of Miami

2
NCT03367754

A Single Dose of Pembrolizumab in HIV-Infected People

Human Immunodeficiency Virus

Other: Placebo|Drug: Pembrolizumab

National Institutes of Health Clinical Center (CC)

1
NCT03367715

A Phase II, Open-label, Single Arm Trial of Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma

MGMT-unmethylated Glioblastoma (GBM)|GBM

Drug: Nivolumab|Drug: Ipilimumab|Radiation: Radiation Therapy (RT)

New York University School of Medicine

2
NCT03366766

Nivolumab, Cisplatin, and Pemetrexed Disodium or Gemcitabine Hydrochloride in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery

Non-Squamous Non-Small Cell Lung Carcinoma|Stage I Non-Small Cell Lung Cancer AJCC v7|Stage IA Non-Small Cell Lung Carcinoma AJCC v7|Stage IB Non-Small Cell Lung Carcinoma AJCC v7|Stage II Non-Small Cell Lung Cancer AJCC v7|Stage IIA Non-Small Cell Lung Carcinoma AJCC v7|Stage IIB Non-Small Cell Lung Carcinoma AJCC v7|Stage IIIA Non-Small Cell Lung Cancer AJCC v7

Biological: Nivolumab|Drug: Cisplatin|Drug: Pemetrexed Disodium|Drug: Gemcitabine Hydrochloride

Sidney Kimmel Cancer Center at Thomas Jefferson University|Bristol-Myers Squibb|Thomas Jefferson University

2
NCT03366155

Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver

Colorectal Cancer|Liver Metastases|Colorectal Adenocarcinoma|Colorectal Cancer With Hepatic Metastases|Colorectal Carcinoma

Drug: Floxuridine|Drug: Oxaliplatin|Drug: Leucovorin|Drug: 5-Fluorouracil|Drug: Irinotecan|Drug: Panitumumab

National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)

2
NCT03366142

Ustekinumab (Anti-IL-12/23p40 Monoclonal Antibody) in Patients With Leukocyte Adhesion Deficiency Type 1 (LAD1) Who Have Inflammatory Pathology

Leukocyte Adhesion Deficiency Type 1

Biological: Ustekinumab

National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)

2
NCT03365882

S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

Colon Adenocarcinoma|ERBB2 Gene Amplification|Rectal Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage III Colon Cancer AJCC v7|Stage III Rectal Cancer AJCC v7|Stage IIIA Colon Cancer AJCC v7|Stage IIIA Rectal Cancer AJCC v7|Stage IIIB Colon Cancer AJCC v7|Stage IIIB Rectal Cancer AJCC v7|Stage IIIC Colon Cancer AJCC v7|Stage IIIC Rectal Cancer AJCC v7|Stage IV Colon Cancer AJCC v7|Stage IV Rectal Cancer AJCC v7|Stage IVA Colon Cancer AJCC v7|Stage IVA Rectal Cancer AJCC v7|Stage IVB Colon Cancer AJCC v7|Stage IVB Rectal Cancer AJCC v7

Biological: Cetuximab|Drug: Irinotecan Hydrochloride|Other: Laboratory Biomarker Analysis|Biological: Pertuzumab|Biological: Trastuzumab|Device: HER-2 testing

Southwest Oncology Group|National Cancer Institute (NCI)

2
NCT03365661

QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML

High-Risk Acute Myeloid Leukemia|Treatment-Related Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Myelodysplastic Syndrome

Biological: ALT-803

Masonic Cancer Center, University of Minnesota|University of Minnesota - Clinical and Translational Science Institute

2
NCT03364348

4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer

HER2 Positive Breast Carcinoma|Recurrent Breast Carcinoma|Stage III Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer

Drug: Utomilumab|Drug: Trastuzumab|Drug: Trastuzumab Emtansine

George W. Sledge Jr.|National Cancer Institute (NCI)|Stanford University

1
NCT03361852

A Pilot Study of a Personalized Neoantigen Cancer Vaccine Following Front-Line Rituximab in Follicular Lymphoma

Follicular Lymphoma

Drug: Rituximab|Biological: Neo Vax

Dana-Farber Cancer Institute

1
NCT03361748

Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma (KarMMa)

Multiple Myeloma

Biological: bb2121 Celgene 2
NCT03369223

An Investigational Immunotherapy Study of BMS-986249 Alone and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread

Advanced Cancer

Biological: BMS-986249|Biological: Nivolumab

Bristol-Myers Squibb

1
2
NCT03362060

PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer

Triple Negative Breast Cancer|Metastatic Breast Cancer

Drug: Pembrolizumab|Biological: PVX-410

Massachusetts General Hospital|Merck Sharp & Dohme Corp.

1
NCT03367377

A Study of LY3209590 in Participants With Type 2 Diabetes

Diabetes Mellitus, Type 2

Drug: LY3209590|Drug: Insulin Glargine

Eli Lilly and Company

1
NCT03363373

Naxitamab for Neuroblastoma With Osteomedullary Disease

Neuroblastoma

Biological: GM-CSF + hu3F8

Y-mAbs Therapeutics

3
 

̿Ǿǰ ӻ Ȳ

NCT Number Title Conditions Interventions Sponsor/Collaborators P
NCT03369210

Liberal Transfusion Strategy in Elderly Patients

Transfusion-dependent Anemia|Surgery|Anemia

Drug: red blood cell transfusion trigger

Dr. Patrick Meybohm, M.D.|Johann Wolfgang Goethe University Hospital

3
NCT03366272

Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients

Lymphoma, Non-Hodgkin

Drug: Nivolumab|Drug: Rituximab|Drug: Gemcitabine|Device: Oxaliplatin

University Hospital, Saarland|Bristol-Myers Squibb|Lymphoma Study Association|University of Leipzig

2
3
NCT03364868

GPPAD-POInT (Global Platform of Autoimmune Diabetes - Primary Oral Insulin Trial)

Diabetes Mellitus, Type 1

Drug: Oral Insulin|Other: Placebo

Technische Universität München|The Leona M. and Harry B. Helmsley Charitable Trust|Helmholtz Zentrum München|University Hospital Carl Gustav Carus|Kinderkrankenhaus auf der Bult|Skane University Hospital|Universitaire Ziekenhuizen Leuven|Medical University of Warsaw|University of Oxford, Clinical Vaccine Research and Immunisation Education

2
NCT03368664

A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT

Multiple Sclerosis

Drug: Alemtuzumab GZ402673|Drug: Glatiramer acetate|Drug: Beta-Interferon|Drug: Methylprednisolone|Drug: Ranitidine|Drug: Ceterizine|Drug: Dexchlorpheniramine|Drug: Paracetamol|Drug: Acyclovir|Drug: Prednisolone

Genzyme, a Sanofi Company|Sanofi

3
NCT03363373

Naxitamab for Neuroblastoma With Osteomedullary Disease

Neuroblastoma

Biological: GM-CSF + hu3F8

Y-mAbs Therapeutics

3
 

 
 


û: info@kobia.kr ()
(06725) ʱ μȯ 333 10, BD 4F

COPYRIGHT(C). ѱ̿Ǿǰȸ, All Rights Reserved.





303ȣ (2017.12.05)
Vol. 67 (December 19, 2017)

Wonderful archive of porn tapes on https://pornsok.com Даркнет магазин Blacksprut Free ebooks Library zlib project z-library Z-Library project Комиксы, Манга читать онлайн на Русском языке Immediate Affinity

Discover the real world of gambling for Korean players at bons casino, a licensed online casino! Hundreds of exciting games for every taste are waiting for you. From classic slots with reels to games with live dealers. BONS Casino offers registration bonuses, free spins, deposit extra funds for games with live dealers, and other promotions! Play and score at BONS CASINO now!